Literature DB >> 7923175

T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report.

X Li1, J Liu, J K Park, T A Hamilton, P Rayman, E Klein, M Edinger, R Tubbs, R Bukowski, J Finke.   

Abstract

Recent data suggest that the poor induction of a T-cell response to human renal cell carcinoma (RCC) may be related to alterations in signal transduction pathways. We report that T cells from RCC patients have two alterations in kappa B motif-specific DNA-binding activity. The first alteration involves the constitutive expression of substantial kappa B-binding activity in nuclear extracts, which was observed in the electrophoretic mobility shift assay. The magnitude of kappa B activity in unstimulated patient T cells was similar to that observed in T cells from normal individuals that had been activated in vitro. On the basis of Western blotting experiments using antibodies to kappa B/Rel family proteins, the kappa B-binding activity constitutively expressed in T cells from RCC patients is composed mostly of the NF-kappa B1 (p50) subunit. The second abnormality in kappa B-binding activity in T cells from these patients is that RelA, a member of the Rel homology family which is part of the normal NF-kappa B complex, was not induced in the nucleus following activation. Western blotting analysis did not detect any RelA in nuclear extracts either before or after stimulation of T cells. The altered kappa B-binding activity in T cells from RCC patients may impair their capacity to respond normally to various stimuli.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923175

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 2.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.

Authors:  R G Uzzo; P Rayman; V Kolenko; P E Clark; M K Cathcart; T Bloom; A C Novick; R M Bukowski; T Hamilton; J H Finke
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 5.  Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives.

Authors:  Patrick Raber; Augusto C Ochoa; Paulo C Rodríguez
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

Review 6.  Allogeneic stem-cell transplantation in renal-cell carcinoma.

Authors:  B M Hayes-Lattin; R T Maziarz; T M Beer
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 7.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 8.  IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells.

Authors:  K S Zier; B Gansbacher
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

Review 9.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.

Authors:  Paulo C Rodríguez; Augusto C Ochoa
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 10.  Signaling defects in anti-tumor T cells.

Authors:  Alan B Frey; Ngozi Monu
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.